key: cord-0992245-ji3meebh
authors: Shah, Sadia Z.; Bryce, Alan H.
title: On the Road Back to Normalcy: Following Science Over Noise in SARS-CoV-2
date: 2021-09-28
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2021.09.011
sha: 29980cfdabdbe6be1fabe976f24d88ce6b8b61c2
doc_id: 992245
cord_uid: ji3meebh

nan

The persistence of the SARS-CoV-2 pandemic, despite the rapid development of effective vaccines, has led to the slowly emerging acceptance that eradication of COVID-19 is unlikely, and that strategies for ongoing management are needed. To that end, ongoing research into disease mechanisms remain vital, and the current article by Dr. Parmar reviews a key mechanism of SARS-CoV-2 infectivity with potential therapeutic significance.

The importance of TMPRSS2 in SARS-CoV-2 was first highlighted in March 2020 by Hoffman and colleagues 1 . This seemingly instantaneous elucidation of a mechanism at the beginning of the pandemic was made possible since SARS-CoV-2 shares ~76% of its amino acid sequence with SARS-CoV, the virus responsible for the SARS outbreak of [2002] [2003] . While that outbreak was successfully contained, it nevertheless led to research which elucidated the key roles of TMPRSS2 and ACE2 for viral entry into human cells [2] [3] [4] . Hoffman and colleagues had the insight to quickly replicate these experiments, and they also demonstrated the TMPRSS2 inhibitor camostat can decrease SARZ-CoV-2 infectivity in cell line studies.

As Dr. Parmar 5 notes, studies of camostat and related TMPRSS2 inhibitors were rapidly launched around the world, including by our group at Mayo Clinic. Our study is testing camostat mesylate, given 4 times daily, in addition to standard of care to hospitalized patients with COVID-19 (NCT04470544). Other studies span the spectrum of disease states from early, minimally symptomatic infections to the severely ill, and given in combination with a variety of different agents (Table 1) . Early results have been mixed. A Danish study randomized 137 hospitalized patients to camostat mesylate at 200mg tid versus placebo, with the primary outcome measure being time to discharge or clinical improvement. The reported a median time to clinical improvement of 5 days in both groups (P = 0·31). The hazard ratio for 30-day mortality in the camostat compared with the placebo group was 0·82 (95% confidence interval [CI], 0·24 to 2·79; P = 0·75) 6 . A similar study in Japan randomized 133 asymptomatic to moderately ill patients to camostat or placebo with a primary endpoint of time to SARS-CoV-2 test negativity and saw no difference 32 . A third negative study, ACTIV-2, enrolled 224 participants in a single arm design which examined changes in viral shedding or symptomatic improvement. The announced results state that the camostat arm failed to reach the predetermined criteria for advancement and has thus been discontinued 33 . In contrast, a South Korean study reported thus far only in a press release announced a 40% faster recovery rate for patients treated with camostat. The benefit was greater in patients over 50 years old, with a >50% improvement in the recovery rate. In that study, 175 patients were randomized to camostat versus placebo 34 .

While the hue and cry of public, media, and political demands may deem such data to be unsatisfactory, experienced scientists and investigators are all too familiar with the difficulty of scientific endeavor and discovery. Progress occurs in fits and starts, or often too slowly then all at once. Further analysis is needed to understand whether the existing data point to drug failure, or flaws or limitations of study design. The results of the remaining ongoing studies should be instructive, and an international consortium of Camostat investigators has already been convened to analyze pooled data.

One possibility is that multi drug inhibition of SAR-CoV-2 entry will ultimately be needed to provide clinically meaningful levels of benefit. Evidence supporting combinations of entry inhibitors over monotherapy already exists with various compounds including the cathepsin inhibitors EST [(23,25) trans-epoxysuccinyl-L-leucylamindo-3-methylbutane ethyl ester] 35 and E64d 1,36 , a proprotein convertase inhibitor 36 , and the protease furin 36 . It may also be that the timing, dosing, or delivery of camostat or other TMPRSS2 inhibitors remains to be optimized, and variations on these parameters such as higher dosing and aerosolized nasal delivery are being pursued.

Ultimately there is every reason to believe that scientific discovery such as that reviewed here by Dr Parmar will stop the endless waves of outbreaks that strain healthcare systems across multitudinous communities. Whether targeting of TMPRSS2 is part of that solution remains to be seen, but insights such as these into disease mechanisms are the vital signposts guiding us back to normalcy. 

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response

Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2

A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry

TMPRSS2: An Equally Important Protease as ACE2 in the Pathogenicity of SARS-CoV-2 Infection

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19

Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus Entry Journal of Virology

Cell entry mechanisms of SARS-CoV-2